SEC Form 4 · accession 0001553878-17-000001
ALNYLAM PHARMACEUTICALS, INC. · ALNY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Akshay Vaishnaw
Officer — EVP, R&D
Period of report
Dec 30, 2016
Accepted (ET)
Jan 4, 2017 · 5:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178670
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 30, 2016 | M | 1,172 | $16.43 | A | 6,922 | D | |
| Common Stock | Dec 30, 2016 | M | 4,019 | $18.66 | A | 10,941 | D | |
| Common Stock | Dec 30, 2016 | M | 4,356 | $21.35 | A | 15,297 | D | |
| Common Stock | Dec 30, 2016 | F | 5,000 | $37.44 | D | 10,297 | D | |
| Common StockF1 | holding | — | — | — | 223 | I | By Managed Account |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $16.43 | Dec 30, 2016 | M | 1,172 | D | — | Dec 9, 2019 | Common Stock | 1,172 | 38,913 | D |
| Stock Option (Right to Buy)F2 | $18.66 | Dec 30, 2016 | M | 4,019 | D | — | Dec 20, 2022 | Common Stock | 4,019 | 45,981 | D |
| Stock Option (Right to Buy)F2 | $21.35 | Dec 30, 2016 | M | 4,356 | D | — | Dec 8, 2018 | Common Stock | 4,356 | 55,994 | D |
Explanation of responses
- F1The reporting person owns 223 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
- F2The stock option vests as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.